Navigation Links
Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
Date:9/7/2012

CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner,  AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity.  AstraZeneca remains committed to this collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity.

AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist, was a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies. As previously announced, a Phase I trial of AZD2820 was halted following a serious adverse event. The decision to discontinue development of the compound was made based on investigations and review conducted by AstraZeneca that followed this incident. While not confirmed, it could not be excluded that the serious adverse event was linked to AZD2820. The investigation further concluded that it is unlikely that the serious adverse event was related to melanocortin receptor activation as an approach for the treatment of obesity.

"We are pleased that the subject has fully recovered from this adverse event," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "The AZD2820 compound is part of a broader research and development collaboration with AstraZeneca. We have multiple classes of collaboration compounds in various stages of preclinical testing and AstraZeneca has informed us that they remain committed to the advancement of collaboration compounds for treatment of obesity."

Pursuant to the terms of the research collaboration and license agreement with AstraZeneca, Palatin is eligible for milestone payments upon achieving development and regulatory milestones and further payments on achievement of sales targets, in addition to royalties on sales of app
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
2. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
3. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
4. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
7. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
10. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
11. Life Technologies to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... "In America," the popular news television program that airs ... by legendary film actor James Earl Jones, has announced that ... segment. , Botany is commonly described as the scientific ... a bit more complicated than that. Scientists and other professionals ... from the smallest bacteria known to man to the largest ...
(Date:3/25/2015)... Agnition announced today that it will be featured ... the first time at 7:30 a.m. CST March 31 ... the extremely important role soil microbes perform in crop ... Catalystâ„¢ technology that enhances soil and plant health for ... again on April 28. , A biochemist at Agnition ...
(Date:3/25/2015)... March 25, 2015  S&P Capital IQ (MHFI) ... Stock Report coverage on Abattis Bioceuticals Corp . ... ATT): is a specialty biotechnology company with capabilities ... and marketing proprietary ingredients, bio-similar compounds, patented equipment ... North America . The company seeks ...
(Date:3/25/2015)... London, UK (PRWEB) March 25, 2015 ... of natural ingredients in all forms of food nutrients, ... led to a substantial rise in demand for natural ... astaxanthin have started to ramp up their capacities to ... for both natural and synthetic source astaxanthin (used in ...
Breaking Biology Technology:Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2
... The Madison-area technology business community has received a ... associate vice chancellor with the University of California at ... not with its resources or industry, but with cultural ... California, billions of dollars have been invested over the ...
... writing my book, I found it helpful to attend ... entrepreneurs, venture capitalists, and corporate lawyers. In my experience, ... piece of the entrepreneurial puzzle, and gave me insights ... following list of seminars, classes, and financial services organizations ...
... trade mission to Japan is building interest in possible ... experiences abroad in a conference call Monday morning. , ... several Wisconsin representatives, Doyle has been speaking at biotechnology ... spent much of today telling people about the value ...
Cached Biology Technology:San Diego success stories become a challenge for the Midwest 2San Diego success stories become a challenge for the Midwest 3San Diego success stories become a challenge for the Midwest 4Starting a high-tech company? Here uFFFDs help 2Starting a high-tech company? Here uFFFDs help 3Starting a high-tech company? Here uFFFDs help 4Starting a high-tech company? Here uFFFDs help 5Doyle builds bridges and hopes for deals in Japan 2Doyle builds bridges and hopes for deals in Japan 3
(Date:3/10/2015)...  Continuing its 167-year history of offering the Best, ... The Eye Scanning Password Authenticator , a device that ... websites or sensitive data. Employing the same ... the device has a small camera that scans and ... converting them into an encrypted ID that cannot be ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
(Date:3/3/2015)... LAKE FOREST, Calif. , March 3, ... ("Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, today announced the ... Hutchinson Cancer Research Centers, ("Fred Hutch") ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
, This press release is available in spanish . Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing, ,...
... Humans are conducting massive experiments on ecosystems around ... species, boosting nutrient concentrations, and altering climates. On ... give the Jane Block Distinguished Lecture in Conservation Biology ... will discuss how our ability to assess these impacts ...
... Department,s National Renewable Energy Laboratory (NREL) recently recognized ... the past year during its Intellectual Property & ... active licenses covering the spectrum of renewable energy ... research and development agreements with industry partners, the ...
Cached Biology News:Public lecture at UC Riverside to discuss challenges in assessing human impact on ecosystems 2NREL staff recognized for breakthrough technologies 2
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_000314 ... Routinely evaluated by immunoblot. ...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
TNR-R2...
Biology Products: